Abstract
<div>Abstract<p>Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. <i>In vitro</i>, the addition of the main PGDS metabolite, PGD<sub>2</sub>, to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. <i>In vitro</i> PGD<sub>2</sub> substitution also enhanced the efficacy of cyclo-oxygenase-2 inhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas. [Mol Cancer Ther 2008;7(10):3420–8]</p></div>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
